Bluejay Diagnostics, Inc.

Bionano Genomics, Inc.

Lucid Diagnostics Inc.

Co-Diagnostics, Inc.

Exact Sciences

Insight Molecular Diagnostics Inc.

NeoGenomics, Inc.

10x Genomics, Inc.

Quest Diagnostics Incorporated

Dilution score: 93/100 (CRITICAL), 5.5 months cash

13F fund flow: neutral, ? institutional managers

23 PubMed publications found for Bluejay Diagnostics, .

From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management.

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Physician Variation in Early Sepsis Management.

ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial.

Short interest: 53.9% of float, squeeze risk: MODERATE

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

<article class="bts-verified-summary" data-ticker="BJDX">
<p>Bluejay Diagnostics, Inc. (BJDX) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>BJDX has 5 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-2">[2]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-06-17) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Bluejay+Diagnostics%2C+Inc.%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">SEC EDGAR · 0001704287 (2026-06-17) <a href="https://efts.sec.gov/LATEST/search-index?q=%22BJDX%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-05-18&amp;enddt=2026-06-17" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001704287

Bluejay Diagnostics, Inc. (BJDX) — BioTechSigns Verified Summary

Bluejay Diagnostics, Inc. (BJDX) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[1].

BJDX has 5 Form 4 insider filings recorded at the SEC in the past 30 days[2].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Bluejay+Diagnostics%2C+Inc.%22&aggFilters=status%3Arec%2Cact
[2] SEC EDGAR, 0001704287. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://efts.sec.gov/LATEST/search-index?q=%22BJDX%22&forms=4&dateRange=custom&startdt=2026-05-18&enddt=2026-06-17

The primary objective of this study is to validate a pre-defined IL-6 concentration cutoff that predicts 28-day mortality in patients who are admitted or are intended to be admitted to the ICU diagnosed with sepsis or septic shock.